Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $98.25 Average Target Price from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been given an average rating of “Moderate Buy” by the four analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $98.75.

Several analysts have recently weighed in on the company. Canaccord Genuity Group reissued a “buy” rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a report on Tuesday, May 21st. DA Davidson raised their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, StockNews.com downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors have recently bought and sold shares of PBH. GAMMA Investing LLC bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at $25,000. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare in the 2nd quarter valued at $26,000. Principal Securities Inc. bought a new position in Prestige Consumer Healthcare in the 4th quarter valued at $29,000. Quest Partners LLC raised its position in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in Prestige Consumer Healthcare by 80.6% in the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

PBH opened at $73.70 on Friday. Prestige Consumer Healthcare has a 12-month low of $56.34 and a 12-month high of $75.31. The firm has a market capitalization of $3.66 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 1.94 and a beta of 0.49. The stock’s 50 day moving average price is $69.43 and its two-hundred day moving average price is $69.14. The company has a quick ratio of 1.90, a current ratio of 3.23 and a debt-to-equity ratio of 0.65.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The company had revenue of $267.10 million for the quarter, compared to analyst estimates of $260.54 million. During the same quarter last year, the firm earned $1.06 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, equities analysts forecast that Prestige Consumer Healthcare will post 4.42 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.